The preliminary findings suggest a potential new direction for managing chronic pain in PTSD, inviting further research and consideration in the clinical field.

Explore the complexities of recently found pathomechanisms, cutting-edge research on emergent molecular pathways, and thorough insights into novel treatment options.

The study on the use of subcutaneous racemic ketamine in treatment-resistant depression underscores the significance of a flexible, individualized dosing approach over a 4-week course.

Results from the TRAILBLAZER-ALZ 2 trial highlight the efficacy of donanemab in slowing the progression of early symptomatic Alzheimer disease over a period of 76 weeks.

With expert-led sessions encompassing a broad spectrum of breast disease management, from genetic risk assessment to cutting-edge oncological treatments, the course is a great opportunity to fortify your practice and enhance patient care.

The use of reticulocyte hemoglobin content (CHr) presents a significant advancement in diagnosing iron-deficiency anemia. CHr’s potential in early detection, differentiation of hematologic conditions, and real-time assessment could pave the way for more precise and timely patient care.